Evaluation of miRNA Detection Methods for the Analytical Characteristic Necessary for Clinical Utilization

Krepelkova, Iveta; Mrackova, Tereza; Izakova, Jana; Dvořáková, Barbora; Chalupová, Lenka; Mikulík, Robert; Slabý, Ondřej; Bartoš, Milan; Růžička, Viktor

doi:10.2144/btn-2019-0021

Cited by 37 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous nanopore-based studies reported sensitivities primarily in the nM range, with a few at pM range, which are insufficient for direct detection in biofluids and therefore requires multiple pre-enrichment or concentration steps 29 , 31 , 49 , 50 . The fM sensitivity reported here represents a major improvement over current single-molecule 21 , 51 or general electrochemical and fluorescence-based 35 techniques and is comparable to amplification-based RT-qPCR 52 . Due to the single-molecule resolution, as little as 5 zeptomol (ca.…”

Section: Discussionmentioning

confidence: 72%

Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miRNAs) play essential roles in post-transcriptional gene expression and are also found freely circulating in bodily fluids such as blood. Dysregulated miRNA signatures have been associated with many diseases including cancer, and miRNA profiling from liquid biopsies offers a promising strategy for cancer diagnosis, prognosis and monitoring. Here, we develop size-encoded molecular probes that can be used for simultaneous electro-optical nanopore sensing of miRNAs, allowing for ultrasensitive, sequence-specific and multiplexed detection directly in unprocessed human serum, in sample volumes as small as 0.1 μl. We show that this approach allows for femtomolar sensitivity and single-base mismatch selectivity. We demonstrate the ability to simultaneously monitor miRNAs (miR-141-3p and miR-375-3p) from prostate cancer patients with active disease and in remission. This technology can pave the way for next generation of minimally invasive diagnostic and companion diagnostic tests for cancer.

show abstract

Section: Discussionmentioning

confidence: 72%

Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Previous data was obtained with RT-qPCR while ours was obtained with miREIA. The miREIA technique is fast, specific and has great correlation with RT-qPCR [ 21 ]. Importantly, it enables easy application of microRNA biomarkers in clinical laboratories that do not have a PCR machine.…”

Section: Discussionmentioning

confidence: 99%

Circulating MicroRNAs and Novel Proteins as Potential Biomarkers of Neurological Complications after Heart Bypass Surgery

Szwed

Kozakiewicz

et al. 2021

JCM

View full text Add to dashboard Cite

Postoperative recovery can be impaired by many conditions, some of which are difficult to diagnose clinically. These include type 2 neurological complications such as hypoactive subtype of postoperative delirium (PD) and early postoperative cognitive dysfunction (ePOCD). Hope for their timely detection may lie with novel biomarkers. Plasma concentrations of microRNA-1-3p, microRNA-21-5p, glial fibrillary acidic protein (GFAP), neuroserpin (NSP), phosphorylated axonal neurofilament subunit H (pNfH) and visinin-like protein 1 (VILIP-1) were investigated in 30 patients undergoing elective off-pump coronary artery bypass grafting. Blood samples were collected at the start and end of a surgery as well as 24 h postoperatively. Associations between the studied biomarkers’ perioperative expression and type 2 neurological complications were analyzed. PD was associated with postoperative expression of GFAP; ePOCD was associated with postoperative expression of microRNA-21-5p and GFAP as well as intraoperative expression of NSP. The predictive accuracy of these molecules was found acceptable, with all their areas under the curve (AUC) values above 0.7. Multivariable regression indicated that microRNA-21-5p, GFAP and NSP were the only significant predictors of ePOCD. Evaluation of a multi-marker model including these three molecules revealed its outstanding predictive accuracy for ePOCD (AUC = 0.95). The use of microRNA-21-5p, GFAP and NSP for monitoring postoperative recovery warrants further research considering their potential to predict PD and ePOCD.

show abstract

“…However, apart from the sensitivity and specificity of the detection, the necessary microarray equipment is fairly expensive as well as the required personnel expertise, and therefore, microarray platforms are rather suitable for miRNA expression surveys concerning a certain disease (Krepelkova et al, 2019;Ouyang et al, 2019).…”

Section: Microarray Platformsmentioning

confidence: 99%

miRNAs in the Diagnosis and Prognosis of Skin Cancer

Neagu

Constantin

Creţoiu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Skin cancer is, at present, the most common type of malignancy in the Caucasian population. Its incidence has increased rapidly in the last decade for both melanoma and non-melanoma skin cancer. Differential expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers, including skin cancers. Since miRNAs' discovery as regulators of gene expression, their importance grew in the field of oncology. miRNAs can post-transcriptionally regulate gene expression, tumor initiation, development progression, and aggressiveness. Nowadays, these short regulatory RNAs are perceived as one of the epigenetic markers for the identification of new diagnostic and/or prognostic molecular markers. Moreover, as miRNAs can drive tumorigenesis, they might eventually represent new therapy targets. Some miRNAs are pleiotropic, such as miR-214, which was found deregulated in several other tumors besides skin cancers. Some others are specific for one or more skin cancer types, like miR-21 and miR-221 for cutaneous melanoma and cutaneous squamous carcinoma or miR-155 for melanoma and cutaneous lymphoma. The goal of this review was to summarize some of the main miRNA detection technologies that are used to evaluate miRNAs in tissues and body fluids. Furthermore, their quantification limits, conformity, and robustness are discussed. Aberrant miRNA expression is analyzed for cutaneous melanoma, cutaneous squamous cell carcinoma (CSCC), skin lymphomas, cutaneous lymphoma, and Merkel cell carcinoma (MCC). In this type of disease, miRNAs are described as potential biomarkers to diagnose early lesion and/or early metastatic disease. In the future, whether in tissue or circulating in body fluids, miRNAs will gain their place in skin cancer diagnosis, prognosis, and future therapeutic targets.

show abstract

Evaluation of miRNA Detection Methods for the Analytical Characteristic Necessary for Clinical Utilization

Cited by 37 publications

References 36 publications

Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum

Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum

Circulating MicroRNAs and Novel Proteins as Potential Biomarkers of Neurological Complications after Heart Bypass Surgery

miRNAs in the Diagnosis and Prognosis of Skin Cancer

Contact Info

Product

Resources

About